Opus Genetics, Inc.

Opus Genetics, Inc. announced its inclusion in the broad-market Russell 3000®, Russell 2000®, and Russell Microcap® Indexes, effective June 29, 2026. This move is part of the June 2026 Russell indexes reconstitution. The company's CEO, George Magrath, highlighted that this inclusion validates their progress in gene therapy development and will enhance their visibility within the investment community. Russell indexes are widely utilized by investment managers, with approximately $12.2 trillion in assets benchmarked against them as of June 2025.

Opus Genetics highlighted five gene therapy programs for inherited retinal diseases (IRDs) at its R&D Science Forum, with four clinical data readouts anticipated in 2027. The company expects three new programs (OPGx-RDH12, OPGx-MERTK, OPGx-RHO) to enter clinical testing within the next 12-18 months. Opus Genetics also reported a cash runway extending into 2029, which is expected to fund multiple clinical milestones and potential product approvals.

Opus Genetics, Inc. presented at its Virtual R&D Science Forum, highlighting its robust pipeline and clinical development strategy for inherited retinal diseases (IRDs). The company announced it is fully-funded to advance five IRD clinical programs, with a cash runway extending into 2029. Key milestones include planned clinical study initiations for RDH12, MERTK, and RHO programs, as well as Phase 3 dosing for LCA5 and initial results for BEST1. The presentation also shared positive efficacy and durability data for OPGx-LCA5, including significant participant-reported improvements.

Opus Genetics, a clinical-stage biopharmaceutical company, announced it will host a virtual Research & Development (R&D) Science Forum on June 16, 2026. The forum will showcase the company's multi-asset gene therapy pipeline for inherited retinal diseases, featuring management and key opinion leaders. It will provide detailed information on three gene therapy programs targeting RDH12, MERTK, and RHO mutations that are entering clinical testing, alongside updates on existing LCA5 and BEST1 clinical programs.

Opus Genetics, Inc. announced that its Compensation Committee approved equity awards for ten new non-executive employees. These awards, granted under the Company's 2021 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), consist of options to purchase an aggregate of 698,000 shares of common stock. The options have an exercise price equal to the fair market value on the grant date and vest over a four-year period.

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, announced that its management will present at the RBC Capital Markets 2026 Global Healthcare Conference. The presentation is scheduled for Tuesday, May 19, 2026, at 11:00 a.m. ET, with a live and archived webcast accessible via the company's investor relations website. Opus Genetics focuses on developing gene therapies for inherited retinal diseases.

Opus Genetics reported a significant net loss of $(65.5) million for Q1 2026, a substantial increase from $(8.2) million in Q1 2025, primarily driven by a $(51.4) million fair value change in warrant liabilities. The company's total stockholders' equity shifted to a deficit of $(45.8) million from a positive $15.3 million at year-end 2025. Despite increased operating cash burn, cash and cash equivalents rose to $59.9 million, further bolstered by a subsequent $34.5 million financing from Oberland Capital.

Opus Genetics reported a net loss of $65.5 million for the first quarter ended March 31, 2026, a significant increase from $8.2 million in the prior year, primarily due to a non-cash expense from warrant liabilities. Despite this, the company announced a strong cash position of approximately $90 million, including recent financing, which is expected to fund operations into 2029. The company also provided positive corporate updates, including encouraging momentum in its OPGx-LCA5 and OPGx-BEST1 gene therapy programs, with key data readouts and clinical advancements anticipated.

Opus Genetics announced a strategic financing agreement with Oberland Capital Management, securing $35 million in senior secured notes and a $5 million equity investment, extending its cash runway into 2029. The company provided a corporate update highlighting significant progress in its gene therapy pipeline, including upcoming data readouts for OPGx-BEST1 in September 2026 and the advancement of OPGx-LCA5 into pivotal Phase 3 trial recruitment. Additionally, earlier-stage programs (RDH12, MERTK, RHO) are expected to enter clinical testing within the next 12 months. For Q1 2026, the company reported a net loss of $65.5 million, significantly higher than the $8.2 million loss in Q1 2025, primarily due to a non-cash expense from warrant liabilities and increased R&D expenses.

Opus Genetics announced positive clinical and preclinical data from its gene therapy programs at the ARVO Annual Meeting 2026. The OPGx-LCA5 program demonstrated robust restoration of cone-mediated vision in pediatric patients with severe LCA5, showing over 30-fold improvements in cone sensitivity and improved visual acuity. Early data from the OPGx-BEST1 program also showed visual acuity gains and improved retinal structure in adult patients. Additionally, preclinical RHO programs exhibited durable retinal preservation and supported clinical translation, highlighting a mutation-independent AAV approach for diverse retinal diseases.